Skip to main navigation

Investor Relations

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
IR Resources

Press Releases

Year

Jun 21, 2022

Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate

Jun 07, 2022

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement

May 13, 2022

Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 11, 2022

Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Apr 11, 2022

Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation

Apr 08, 2022

Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

Apr 01, 2022

Kiromic Biopharma Announces Filing of Form 12b-25

Mar 11, 2022

Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results

Feb 03, 2022

Kiromic BioPharma Announces Changes in Management, Board of Directors

Feb 03, 2022

Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors

Investor Tools

Print

RSS Feeds

Email Alerts

Investor Contact

Copyright © 2022 Kiromic BioPharma, Inc. All rights reserved.